Recurrent somatic mutations in ETNK1 (Ethanolamine-Kinase-1) were identified in several myeloid malignancies and are responsible for a reduced enzymatic activity. Here, we demonstrate in primary leukemic cells and in cell lines that mutated ETNK1 causes a significant increase in mitochondrial activity, ROS production, and Histone H2AX phosphorylation, ultimately driving the increased accumulation of new mutations. We also show that phosphoethanolamine, the metabolic product of ETNK1, negatively controls mitochondrial activity through a direct competition with succinate at mitochondrial complex II. Hence, reduced intracellular phosphoethanolamine causes mitochondria hyperactivation, ROS production, and DNA damage. Treatment with phosphoethanolamine is able to counteract complex II hyperactivation and to restore a normal phenotype.

Fontana, D., Mauri, M., Renso, R., Docci, M., Crespiatico, I., Rost, L., et al. (2020). ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. NATURE COMMUNICATIONS, 11(1) [10.1038/s41467-020-19721-w].

ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine

Fontana D.;Crespiatico I.;D'Aliberti D.;Massimino L.;Bertagna M.;Zambrotta G.;Bossi M.;Fanelli F.;Cassina V.;Salerno D.;Nardo L.;Chinello C.;Mantegazza F.;Magni F.;Cavaletti G.;Gambacorti-Passerini C.;Piazza R.
2020

Abstract

Recurrent somatic mutations in ETNK1 (Ethanolamine-Kinase-1) were identified in several myeloid malignancies and are responsible for a reduced enzymatic activity. Here, we demonstrate in primary leukemic cells and in cell lines that mutated ETNK1 causes a significant increase in mitochondrial activity, ROS production, and Histone H2AX phosphorylation, ultimately driving the increased accumulation of new mutations. We also show that phosphoethanolamine, the metabolic product of ETNK1, negatively controls mitochondrial activity through a direct competition with succinate at mitochondrial complex II. Hence, reduced intracellular phosphoethanolamine causes mitochondria hyperactivation, ROS production, and DNA damage. Treatment with phosphoethanolamine is able to counteract complex II hyperactivation and to restore a normal phenotype.
Articolo in rivista - Articolo scientifico
Cell Line; Cell Respiration; DNA Breaks; Electron Transport Complex II; Ethanolamines; Humans; Leukemia, Myeloid; Mitochondria; Mutation; Phenotype; Phosphotransferases (Alcohol Group Acceptor); Reactive Oxygen Species; Succinic Acid; Tigecycline
English
Fontana, D., Mauri, M., Renso, R., Docci, M., Crespiatico, I., Rost, L., et al. (2020). ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. NATURE COMMUNICATIONS, 11(1) [10.1038/s41467-020-19721-w].
Fontana, D; Mauri, M; Renso, R; Docci, M; Crespiatico, I; Rost, L; Jang, M; Niro, A; D'Aliberti, D; Massimino, L; Bertagna, M; Zambrotta, G; Bossi, M; Citterio, S; Crescenzi, B; Fanelli, F; Cassina, V; Corti, R; Salerno, D; Nardo, L; Chinello, C; Mantegazza, F; Mecucci, C; Magni, F; Cavaletti, G; Bruheim, P; Rea, D; Larsen, S; Gambacorti-Passerini, C; Piazza, R
File in questo prodotto:
File Dimensione Formato  
2020 Nat Comm_free.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 2.93 MB
Formato Adobe PDF
2.93 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/298474
Citazioni
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 8
Social impact